Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma

NCT05236036 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05236036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 8, 2022
Completion date
January 3, 2029
Enrollment
86 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioblastoma, glioblastoma, idh-wildtype, mgmt-unmethylated glioblastoma, recurrent glioblastoma